Search company, investor...
Eisbach Bio company logo

Eisbach Bio

Founded Year



Grant - II | Alive

Total Raised


Last Raised

$7.73M | 2 yrs ago

About Eisbach Bio

Eisbach Bio is a biotechnology company targeting the molecular machines that drive human disease. Eisbach is using its allosteric inhibitor platform to develop selective drugs for the inhibition of complex molecular machines involved in serious diseases. In cancer, it has identified synthetic-lethal and oncogenic helicases as targets and developed small-molecule inhibitors targeting specific chromatin remodeling enzymes. Using its helicase expertise, the company also developed an inhibitor of the SARS-CoV-2 helicase Nsp13, an RNA helicase critical for viral replication and the most conserved non-structural protein within the coronavirus family.

Headquarters Location

Am Klopferspitz 19

Munich, 82152,


+49 89 2153790-0

Missing: Eisbach Bio's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Eisbach Bio's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Eisbach Bio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Eisbach Bio is included in 1 Expert Collection, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Latest Eisbach Bio News

Eisbach Bio surfs synthetic lethal wave

Feb 4, 2022

Feb. 4, 2022 “The premise of our whole company is that we target molecular machines, but we don’t target the engine,” Adrian Schomburg told BioWorld. Instead, “we interfere with the throttle and other highly specific controls of these machines.” “We,” in this case, is Eisbach Bio GmbH, a German startup that is developing anticancer programs aimed at exploiting synthetic lethality by targeting helicases. Founded in 2019, the company has three programs, a recently announced collaboration with MD Anderson Cancer Center in oncology, and another program in COVID-19.

Eisbach Bio Frequently Asked Questions (FAQ)

  • When was Eisbach Bio founded?

    Eisbach Bio was founded in 2019.

  • Where is Eisbach Bio's headquarters?

    Eisbach Bio's headquarters is located at Am Klopferspitz 19, Munich.

  • What is Eisbach Bio's latest funding round?

    Eisbach Bio's latest funding round is Grant - II.

  • How much did Eisbach Bio raise?

    Eisbach Bio raised a total of $17.17M.

  • Who are the investors of Eisbach Bio?

    Investors of Eisbach Bio include Bavarian Ministery of Economics and Bundesministerium fur Bildung und Forschung.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.